



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/052,798	11/02/2001	Camellia W. Adams	P1101R2D1

09157  
GENENTECH, INC.  
1 DNA WAY  
SOUTH SAN FRANCISCO, CA 94080



CONFIRMATION NO. 4012

## FORMALITIES LETTER



\*OC000000007491110\*

Date Mailed: 02/19/2002

## NOTICE TO FILE CORRECTED APPLICATION PAPERS

*Filing Date Granted*

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- A substitute specification in compliance with 37 CFR 1.52 because:
  - Papers contain improper margins. *Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4")*
- Substitute drawings in compliance with 37 CFR 1.84 because:
  - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. ( 5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



04-19-02

0300

#5

Patent Docket P1101R2D1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Camellia W. Adams et al. Serial No.: 10/052,798 Filed: November 2, 2001 For: APO-2 RECEPTOR	 Group Art Unit: To Be Assigned Examiner: To Be Assigned CONFIRMATION NO: 4012  <b>CERTIFICATE OF EXPRESS MAILING</b> Express Mail Number: EV-016 026 717 US I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Assistant Commissioner of Patents, Washington, D.C. 20231." April 17 2002  Diane L. Marschang
--	---

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS  
AND  
PRELIMINARY AMENDMENTAssistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

This paper is being filed in response to the Notice to File Corrected Application Papers - Filing Date Granted dated February 19, 2002. Transmitted herewith are a substitute specification (117 pages), twenty (20) sheets of Formal Drawings, and a copy of Notice to File Corrected Application Papers. Entry of these documents and the preliminary amendment (below) into the application file is respectfully requested. These amendments and the preliminary amendment previously filed on November 2, 2001 are requested for entry and consideration prior to examination on the merits.

In the specification:

Please enter the substitute specification comprising 117 pages into the application file.

On page 11, in the paragraph on lines 12-14, the text has been amended to read as follows:

—Figure 1 (illustrated as Figures 1A-1C) shows the nucleotide sequence of a native sequence human Apo-2 cDNA (SEQ ID NO:2) and its derived amino acid sequence (SEQ ID NO:1). ---



REMARKS

In response to the Notice mailed February 19, 2002, Applicants are submitting herewith formal drawings in compliance with 37 CFR 1.84. The specification has also been amended on page 11, as shown above, to correct the numbering in the BRIEF DESCRIPTION OF THE DRAWINGS to reflect the numbering for formal figures 1A-1C.

A substitute specification in compliance with 37 CFR 1.52 is also submitted herewith. It is requested that this substitute specification be entered in the application file. The substitute specification is identical in content to the application as originally filed on November 2, 2001, but has been re-formatted to comply with proper margin requirements. Accordingly, the undersigned hereby certifies that no new matter is being introduced in the substitute specification.

The amendment to the specification is illustrated in the attached paper entitled "Marked Up Version to Show Changes Made." A clean copy of the amended text is provided above.

It is Applicants' understanding that there is no fee associated with this response, however, in the event that the Patent Office determines that a fee is due in connection with the filing of this document, we hereby authorize the Commissioner to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

By:

*Diane L. Marschang*

Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE



MARKED UP VERSION TO SHOW CHANGES MADE

In the specification:

Please enter the substitute specification comprising 117 pages into the application file.

On page 11, in the paragraph on lines 12-14, the text has been amended as follows:

—Figure 1 (illustrated as Figures 1A-1C) shows the nucleotide sequence of a native sequence human Apo-2 cDNA (SEQ ID NO:2) and its derived amino acid sequence (SEQ ID NO:1). ---

11/11/01 11:11:11 AM